A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Recruiting

Phase 1

Phase 2

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT03972657

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clear Cell Renal Cell Carcinoma (ccRCC)

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REGN5678

Cemiplimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information